CRISPR Therapeutics - CRSP Stock Forecast, Price & News

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CRSP shares. Chardan Capital decreased their price target on CRISPR Therapeutics from $164.00 to $154.00 and set a "buy" rating on the stock in a research note on Tuesday, August 9th. Needham & Company LLC dropped their target price on CRISPR Therapeutics from $170.00 to $122.00 in a research report on Friday, May 13th. BMO Capital Markets initiated coverage on CRISPR Therapeutics in a research note on Thursday, June 16th. They issued an "outperform" rating and a $98.00 target price on the stock. Oppenheimer reduced their price objective on CRISPR Therapeutics from $150.00 to $122.00 and set an "outperform" rating on the stock in a research note on Thursday, June 23rd. Finally, Credit Suisse Group increased their target price on shares of CRISPR Therapeutics from $74.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $112.33.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $72.15 on Friday. The company has a market capitalization of $5.63 billion, a PE ratio of -8.77 and a beta of 1.93. CRISPR Therapeutics has a 52 week low of $42.51 and a 52 week high of $129.50. The company has a 50 day moving average price of $72.90 and a two-hundred day moving average price of $64.03.

CRISPR Therapeutics (NASDAQ:CRSP - Get Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.21) by ($0.19). The business had revenue of $0.20 million during the quarter, compared to analyst estimates of $2.20 million. CRISPR Therapeutics had a negative net margin of 4,274.02% and a negative return on equity of 27.40%. The company's revenue was down 100.0% compared to the same quarter last year. During the same quarter last year, the company posted $9.44 earnings per share. On average, sell-side analysts forecast that CRISPR Therapeutics will post -9.23 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $61.59, for a total value of $1,539,750.00. Following the completion of the sale, the chief executive officer now owns 290,279 shares in the company, valued at approximately $17,878,283.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.30% of the stock is owned by company insiders.